Abstract B064: Racial disparities in bone and soft-tissue sarcomas: An analysis of the Surveillance, Epidemiology, and End Results program

Introduction Bone and soft-tissue sarcomas comprise a broad yet heterogenous group of malignancies, separately classified into at least 70 different histological diseases. In the United States, approximately 15,000 cases of bone and soft-tissue sarcomas are annually diagnosed, roughly representing 1% of all incident cancer diseases. Health disparities exist for cancer patients of different racial identities, but research on patients with soft-tissue and bone sarcomas is still debatable. This analysis elucidates racial discrepancies in epidemiological measures among patients with such diseases. Methods The Surveillance, Epidemiology, and End Results database was queried between 2000 and 2020 for patients with bone or soft-tissue sarcomas. Metrics, consisting of prevalence, incidence, and incidence-based mortality rates, as well as case-fatality ratios were computed. Multivariate survivorship analyses controlling for age, sex, race, tumor size, stage, and grade were performed to identify independent predictors of survival. Results The most and least frequently diagnosed subtypes of bone and soft-tissue sarcomas were leiomyosarcoma and lymphangiosarcoma with an average of 889.6 and 1.3 cases per year, respectively. Malignancies were all primarily identified in White patients compared to subjects of other races. From 2000 to 2020, the prevalence of fibrosarcoma significantly increased for non-White and non-Black individuals and the prevalence of dermatofibrosarcoma decreased only for White individuals (both, p